XML 90 R56.htm IDEA: XBRL DOCUMENT v3.24.1
Licenses and Collaborations - Additional Information (Detail) - USD ($)
$ in Thousands
9 Months Ended 12 Months Ended
Oct. 31, 2020
Sep. 30, 2022
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
License And Collaborations [Line Items]              
Research and development     $ 78,225 $ 68,993      
Ares Agreement [Member] | Ares Trading S A [Member]              
License And Collaborations [Line Items]              
Temporary equity shares issued during the period value $ 13,100            
Milestone payments payable           $ 25,000  
Related party transaction, expenses from transactions with related party     2,800 $ 4,500      
Ares Agreement [Member] | Ares Trading S A [Member] | Achievement Of Specified BLA Filing Or Regulatory Approval Milestones [Member]              
License And Collaborations [Line Items]              
Milestone payments payable           $ 176,500  
Ares Agreement [Member] | Ares Trading S A [Member] | Achievement Of Specified Commercial Milestones [Member]              
License And Collaborations [Line Items]              
Milestone payments payable             $ 515,000
Amplyx Agreement [Member]              
License And Collaborations [Line Items]              
Milestone payments payable         $ 2,000    
Acquisition cost         5,000    
Research and development   $ 3,700     7,000    
Reduction in contingent future development   7,000          
Contingent milestone obligation accrued         $ 2,000    
Company shares issued   $ 5,700          
Amplyx Agreement [Member] | Amplyx and Novartis [Member] | Achievement of Various Clinical Development and Regulatory Milestones [Member]              
License And Collaborations [Line Items]              
Milestone payments payable     7,000        
Novartis [Member] | Amplyx and Novartis [Member] | Achievement of Various Clinical Development and Regulatory Milestones [Member]              
License And Collaborations [Line Items]              
Milestone payments payable     $ 62,000        
Common Class A [Member]              
License And Collaborations [Line Items]              
Issuance of common stock for payment of licensing fees, net of offering costs, shares   283,034   283,034      
Common Class A [Member] | IPO [Member]              
License And Collaborations [Line Items]              
Conversion of redeemable convertible preferred stock to common stock 1,913,501